2 hours ago
1
narvikk
Inventiva (NASDAQ:IVA) climbed ~15% on Wednesday after Piper Sandler launched its coverage with an Overweight recommendation, citing the French biotech’s lead candidate, lanifibranor, targeted at the liver condition metabolic dysfunction-associated steatohepatitis (MASH).
Analyst Yasmeen Rahimi, with a $26 per share target on
English (US) ·